Get started
Author

Anna Kruschinski

Observed names: A Kruschinski, A. Kruschinski, Kruschinski, Anna
OpenAlex ID: A5005313731
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
2013 · Julia Hoellenriegel, Dirk Zboralski, et al. · Blood · 244
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
2008 · Anna Kruschinski, Andreas Moosmann, et al. · Proceedings of the National Academy of Sciences · 197
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy
2014 · Aldo M. Roccaro, Antonio Sacco, et al. · Cell Reports · 136
PDF
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats
2013 · Shie-Chau Liu, Reem Alomran, et al. · Neuro-Oncology · 95
PDF
Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12
2013 · A Vater, J Sahlmann, et al. · Clinical Pharmacology & Therapeutics · 84
PDF
Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFNγ
2014 · Ana Textor, Joanna J. Listopad, et al. · Cancer Research · 82
PDF
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
2017 · H Ludwig, K Weisel, et al. · Leukemia · 80
PDF
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition
2017 · Ellen L. Weisberg, Martin Sattler, et al. · Oncotarget · 25
PDF
CXCL12/SDF-1-Dependent Retinal Migration of Endogenous Bone Marrow-Derived Stem Cells Improves Visual Function after Pharmacologically Induced Retinal Degeneration
2016 · Volker Enzmann, Stéphanie Lecaudé, et al. · Stem Cell Reviews and Reports · 25
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21
2015 · Sylvia Ganghammer, Evelyn Hutterer, et al. · Oncotarget · 21
PDF
Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia
2015 · Rodrigo Omar Jacamo, Hong Mu, et al. · Blood · 17
Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia
2014 · Michael Steurer, Marco Montillo, et al. · Blood · 12
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma
2014 · Heinz Ludwig, Katja Weisel, et al. · Blood · 10
Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study
2013 · Marco Gobbi, Michael Steurer, et al. · Blood · 10
Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study
2013 · Heinz Ludwig, Katja Weisel, et al. · Blood · 9
SDF-1 Inhibition Using Spiegelmer® Nox-A12 As a Novel Strategy For Targeting AML Cells Within Their BM Microenvironment
2013 · Rodrigo Jacamo, Zhihong Zeng, et al. · Blood · 4
CXCL12 Inhibition By Nox-A12 (Olaptesed Pegol) Synergizes with the ADCC Activity of CD20 Antibodies By Increasing NK Cell Infiltration in a 3D Lymphoma Model
2016 · Dirk Zboralski, Anna Kruschinski, et al. · Blood · 3
Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization
2012 · Dirk Zboralski, Julia Hoellenriegel, et al. · Blood · 3
Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
2012 · Marco Gobbi, Federico Caligaris-Cappio, et al. · Blood · 3
In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches
2012 · Aldo M. Roccaro, Antonio Sacco, et al. · Blood · 3
The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,
2011 · Julia Hoellenriegel, Dirk Zboralski, et al. · Blood · 3
CXCL12 inhibition with NOX-A12 (olaptesed pegol) increases T and NK cell infiltration and synergizes with immune checkpoint blockade in tumour-stroma spheroids
2016 · D. Zboralski, A. Kruschinski, et al. · Annals of Oncology · 2
Interim Results From a Phase Iia Study of the Anti-cxcl12 Spiegelmer Olaptesed Pegol (nox-a12) in Combination With Bendamustine/rituximab in Patients With Chronic Lymphocytic Leukemia
2014 · Michael Steurer, Lydia Scarfò, et al. · Haematologica · 2
The Spiegelmer® Nox-A12 Abrogates Homing Of Human CLL Cells To Bone Marrow and Mobilizes Murine CLL Cells In The Eμ-TCL1 Transgenic Mouse Model Of CLL
2013 · Elisabeth Hinterseer, Tamara Girbl, et al. · Blood · 2
Abstract PR14: In vivo targeting of stromal-derived factor-1 as a strategy to prevent myeloma cell dissemination to distant bone marrow niches
2015 · Aldo M. Roccaro, Antonio Sacco, et al. · Cancer Research · 1
Works count: 45
Citation count: 1,080
H-index: 12
I10-index: 14
Year
Topic
Type